Literature DB >> 10445569

Bromfenac (Duract)-associated hepatic failure requiring liver transplantation.

E B Hunter1, P E Johnston, G Tanner, C W Pinson, J A Awad.   

Abstract

Bromfenac sodium (Duract) is a phenylacetic acid-derived nonsteroidal anti-inflammatory agent introduced in the United States in 1997 and withdrawn in 1998. We describe the first case of fulminant hepatic failure associated with this agent treated successfully with liver transplantation. Similarities to hepatotoxicity with related agents is discussed.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10445569     DOI： 10.1111/j.1572-0241.1999.01321.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


  13 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

2.  Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.

Authors:  Allen D Brinker; Jenna Lyndly; Joseph Tonning; David Moeny; Jonathan G Levine; Mark I Avigan
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

Review 3.  Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

Authors:  Fernando Bessone
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

Review 4.  Managing the challenge of chemically reactive metabolites in drug development.

Authors:  B Kevin Park; Alan Boobis; Stephen Clarke; Chris E P Goldring; David Jones; J Gerry Kenna; Craig Lambert; Hugh G Laverty; Dean J Naisbitt; Sidney Nelson; Deborah A Nicoll-Griffith; R Scott Obach; Philip Routledge; Dennis A Smith; Donald J Tweedie; Nico Vermeulen; Dominic P Williams; Ian D Wilson; Thomas A Baillie
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 5.  Mechanisms of drug-induced liver injury.

Authors:  Michael P Holt; Cynthia Ju
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 6.  Cutaneous drug reactions in children: an update.

Authors:  Kara Heelan; Neil H Shear
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

7.  Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses.

Authors:  Lisl Km Shoda; Christina Battista; Scott Q Siler; David S Pisetsky; Paul B Watkins; Brett A Howell
Journal:  Gene Regul Syst Bio       Date:  2017-05-30

8.  Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.

Authors:  Ester Carreño; Alejandro Portero; David J Galarreta; José M Herreras
Journal:  Clin Ophthalmol       Date:  2012-04-27

Review 9.  Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.

Authors:  Lise Aagaard; Ebba Holme Hansen
Journal:  BMC Clin Pharmacol       Date:  2009-03-03

10.  Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.

Authors:  Jeffrey L Woodhead; William J Brock; Sharin E Roth; Susan E Shoaf; Kim L R Brouwer; Rachel Church; Tom N Grammatopoulos; Linsey Stiles; Scott Q Siler; Brett A Howell; Merrie Mosedale; Paul B Watkins; Lisl K M Shoda
Journal:  Toxicol Sci       Date:  2016-09-21       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.